Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The companys mid- and early-stage pipeline products comprise Mapatumumab for the treatment of non-small cell lung cancer, multiple myeloma, and hepatocellular cancer; IAP Inhibitors that are compounds, which block the activity of IAP (inhibitor of apoptosis) proteins, allowing apoptosis to proceed and causing the cancer cells to die; and CCR5 mAb, a human monoclonal antibody to the CCR5 receptor for the treatment of ulcerative colitis. Human Genome Sciences, Inc. also holds financial rights to certain products in the GlaxoSmithKline clinical development pipeline, including darapladib, a Phase III clinical trial product for the treatment of coronary heart disease and ischemic stroke; and Albiglutide for the treatment for type 2 diabetes, which is in Phase III clinical trial stage. The company has a license agreement with GlaxoSmithKline for the co-development and commercialization of BENLYSTA; and a collaboration and license agreement with Aegera Therapeutics, Inc. to develop and commercialize certain oncology molecules and related backup compounds. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for HGSI